• Abcellera announced a significant preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals to discover and develop next-generation T-cell engaging multispecific antibodies.
  • The deal includes $56 million in upfront payments to Abcellera and up to $792 million in potential option fees and milestone payments, totaling up to $848 million for any program Jazz exercises.
  • The collaboration will leverage Abcellera's antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors.